Vera Therapeutics - Class A opened lower at $30.30, compared with its previous close of $30.53. In the last trading session, the stock traded between $29.56 and $31.15. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Vera Therapeutics - Class A is now worth
$ 158.97
giving a profit of
$ 58.97 (58.97%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
+$0.23 (+0.75%)
Day High
$31.15
Day Low
$29.56
Day Open
$30.30
Prev Close
$30.53
Volume
4,43,685
1W Return
5.80%
1M Return
-4.98%
3M Return
-5.42%
6M Return
-14.17%
1Y Return
4.77%
Market Cap ($ Mn)
2,217
PE Ratio
-
PB Ratio
6.03
PEG Ratio
-
ROE
-57.98%
ROCE
-54.20%
EPS (TTM)
$-1.52
1 Week
5.80%
1 Month
-4.98%
3 Months
-5.42%
6 Months
-14.17%
9 Months
-31.64%
Vera Therapeutics grants inducement stock awards to five new employees
Granted options for 16,700 shares and RSUs for 8,350 shares to five new employees. Stock options priced at $32.38, equal to closing price on September 29, 2026. Awards vest over four years under Nasdaq Listing Rule 5635(c)(4).
27 days agoVera Therapeutics to present TRUTAKNA ORIGIN 3 data at ASN Kidney Week
Vera Therapeutics will present final ORIGIN 3 efficacy data for TRUTAKNA at ASN Kidney Week 2026. The presentation includes a late-breaking oral slot and a research poster for the pivotal trial. Five total abstracts will be presented, covering adult, pediatric, and real-world evidence. Interim PIONEER trial results for membranous nephropathy also scheduled for late-breaking oral.
28 days agoVera Therapeutics Trutakna meets all endpoints in IgA nephropathy trial
Trutakna met all prespecified endpoints in the ORIGIN 3 trial for primary IgA nephropathy. Mean eGFR change at 52 weeks was -0.1 mL/min/1.73m² for Trutakna vs -5.7 for placebo. Risk of composite kidney disease progression reduced by 76% through 104 weeks. Zero patients in Trutakna group required dialysis, transplant, or died vs eight in placebo.
1mo agoVera Therapeutics grants inducement stock awards to six new employees
Vera Therapeutics granted 61,500 stock options and 30,750 RSUs to six new employees. Stock options have an exercise price of $34.23, set at the September 1, 2026 closing price. Awards vest over four years, contingent on continued employee service. Grants were approved under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
1mo agoVera Therapeutics to present at Cantor and Morgan Stanley conferences
Vera Therapeutics management to present at Cantor and Morgan Stanley conferences in September 2026. Events include fireside chats and one-on-one investor meetings in New York. Webcasts available live and as replays for 90 days post-event. Company focuses on autoimmune disease treatments, led by TRUTAKNA™.
1mo agoHC Wainwright lowers Vera Therapeutics price target to $90
HC Wainwright & Co. analyst Arthur He maintains a Buy rating on Vera Therapeutics (NASDAQ: VERA) but cuts the price target from $125 to $90. The move signals a more conservative valuation view while preserving the bullish long-term outlook.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Vera Therapeutics - Class A is now worth
$ 158.97
giving a profit of
$ 58.97 (58.97%)
Note: Past profits do not guarantee future returns.
